⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770522 | 0.83 | — | — | |
| SCHEMBL351014 | 0.70 | — | — | |
| SCHEMBL3698374 | 0.68 | — | — | |
| SCHEMBL352623 | 0.62 | — | — | |
| SCHEMBL13280431 | 0.60 | — | — | |
| SCHEMBL2049131 | 0.60 | — | — | |
| SCHEMBL334983 | 0.60 | — | — | |
| SCHEMBL2920342 | 0.59 | — | — | |
| SCHEMBL2223430 | 0.58 | — | — | |
| SCHEMBL18612399 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2020-02-13 | — | — | US | claimed |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2016-07-21 | — | — | US | claimed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | claimed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | claimed |
| EP-2685986-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2014-01-22 | — | — | EP | claimed |
| WO-2012129084-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-09-27 | — | — | WO | claimed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| EP-4396176-A1 | INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240189322-A1 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | GENZYME CORPORATION | 2024-06-13 | — | — | US | disclosed |
| WO-2024102810-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2008139288-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007036769-A1 | AMINOTHIAZOLE DERIVATIVES AS AGONISTS OF THE THROMBOPOIETIN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007004038-A1 | AMINOTHIAZOLE DERIVATIVES AS AGONISTS OF THE THROMBOPOIETIN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |